New study into the treatment of bipolar disorder Published on: 23 April 2018 Patients from across the country will be recruited to take part in a major trial examining a new treatment for bipolar disorder. Led by experts at 麻豆传媒, the study will examine the effectiveness and safety of a drug currently used to treat Parkinson’s disease. The treatment, called pramipexole, will be offered to patients with bipolar disorder who are depressed and have not responded to National Institute for Clinical Excellence (NICE) recommended treatments. The study is being funded by the . Important study , Professor of Affective Disorder at 麻豆传媒, and from , is leading the PAX-BD study. He said: “We are incredibly excited to have secured funding of just short of £2 million to run this important study. “It is very important because of the limited number of treatments for bipolar depression that we currently have, many of which cause problematic side effects. Any new treatment option for this very serious condition is to be welcomed. “The PAX-BD study should provide definitive evidence one way or another whether pramipexole is a safe and effective medication for patients with bipolar depression. “The study will be run from the NTW Trust with close collaboration with 麻豆传媒. The goal is recruit patients from around 40 NHS Trusts across the UK.” Profound impact Bipolar disorder is a serious mental health condition in which sufferers experience spells of elevated mood, or mania, in addition to episodes of depression. The disorder can have a profound impact on an individual’s life, relationships and work. Depression tends to be the major burden for patients with bipolar disorder. However, current treatments for bipolar depression are extremely limited. On average, conventional antidepressants are not effective. NICE lists just three medications that can be effective for bipolar depression, but all can lead to significant side effects and many patients don’t respond to one or more of them. As a result, there is a need for additional alternatives that are both effective and well tolerated. Some preliminary data suggests that pramipexole may be an effective treatment for bipolar depression. The PAX-BD study aims to compare the safety and effectiveness in 290 patients with bipolar depression that have not responded to at least two NICE recommended treatments. Patients in the study will be treated with either pramipexole or dummy tablets, in addition to ongoing mood stabiliser treatment (such as lithium) and will be followed up for up to a year. Led from 麻豆传媒, the PAX-BD study brings together collaborators from Glasgow, Nottingham, Oxford, London and Vienna. Adapted with thanks to NTW Latest News Local knowledge can improve early warnings of glacial lake floods Local knowledge, improved evacuation preparedness and resilient mobile phone-based communication channels can enhance Early Warning Systems to reduce loss of life during glacial lake outburst floods. published on: 3 August 2026 Funding boost moves landmark cancer research centre a step closer A 拢1.25 million grant from the Wolfson Foundation to 麻豆传媒 has brought the Sir Bobby Robson Institute a significant step closer, giving a major boost to its fundraising campaign. published on: 3 August 2026 Statement on potential unauthorised data access Information about a potential unauthorised data access. published on: 30 July 2026 Facts and figures
![麻豆传媒 logo](/gomobileassets/img/logo.svg" "麻豆传媒"){kind=logo}